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Bioorthogonal Prodrug–Prodrug Activation 
Kevin Neumann,*a† Alessia Gambardella,a† Annamaria Lilienkapfa and Mark Bradley*a 
 
The selective and biocompatible activation of prodrugs within complex biological systems remains a key challenge in medical 
chemistry and chemical biology. Herein we report, for the first time, a dual prodrug activation strategy that fully satisfies 
the principle of bioorthogonality by the symbiotic formation of two active drugs without the generation of any by-products. 
This dual and traceless prodrug activation strategy takes advantage of the INVDA chemistry of tetrazines (here a prodrug), 
generating a pyridazine-based miR21 inhibitor and the anti-cancer drug camptothecin, and offers a new concept in prodrug 
activation.
Introduction 
Conventional prodrug activation strategies typically rely on 
physiological changes e.g. pH around a tumor or a specific 
biological stimulus for example the expression of an enzyme to 
“switch-on” or activate the prodrug.1 An alternative approach2,3  
is the application of chemical reactions that can take place 
within a biological environment with high selectivity and 
biocompatibility,4 with such reactions typically being 
“unnatural” in origin. Bioorthogonal reactions have found 
applications in drug activation and delivery, and include 
examples of prodrug activation and even in situ drug synthesis.5 
Examples of bioorthogonal prodrug activations include 
application of the Staudinger reaction and strain-promoted 
alkene–azide cycloaddition that have been used to activate 
prodrugs of doxorubicin.6,7,8 More broadly, bioorthogonal 
reactions have enabled the rapid and selective labelling of 
proteins,9,10 glycans,11 lipids12 and DNA13 under physiological 
conditions often in a pre-targeted imaging scenario.14,15,16 
 
Since the inverse electron demand Diels–Alder (INVDA) reaction 
between tetrazines and electron-rich dienophiles was first 
described as a bioorthogonal reaction,17 the tetrazine promoted 
INVDA reaction has been the subject of intense interest. This 
includes a series of studies where tetrazine quenched 
profluorophores undergo “switch-on” of fluorescence upon 
treatment with a dienophile,19,20,21 while tetrazine chemistry 
has been used to label pre-targeted antibodies with PET 
isotopes.22,23,24 Thus, tetrazine-mediated INVDA chemistry has 
shown to offer high chemical selectivity and to be fast, efficient 
and biologically compatible, undoubtedly enhanced by the 
acceleration shown in water for all Diels–Alder chemistries.18 
Yet, despite their extensive use in imaging, examples of 
tetrazine-mediated prodrug activation are limited, but include 
a trans-cyclooctene–doxorubicin conjugate that liberates the 
drug following reaction with a tetrazine and subsequent 
oxidation of the resulting 1,4-dihydropyridazine to the 
pyridazine.25,26 This approach was recently adapted to allow the 
release of carbonyl sulphide (OCS) that was converted, via 
carbonic anhydrase, to the gasotransmitter H2S.27 Recently, we 
and others, have shown that vinyl ethers undergo facile 
reaction with tetrazines resulting in elimination of the 
corresponding alkoxide or phenoxide.28,29,30 Thus, polymeric 
nanoparticles, bearing a vinyl ether caged linker, were shown to 
liberate doxorubicin upon treatment with a tetrazine resulting 
in “switch-on” of cytotoxicity.28 
 
Here, we report a new concept in prodrug activation with the 
simultaneous, dual, and fully traceless (except the loss of N2) 
activation/generation of two different drugs. This chemistry 
utilizes tetrazine as a masked prodrug, which removes the vinyl 
ether from a second prodrug and incorporated the structural 
elements of the vinyl group into its own structure, giving rise to 
two active drugs (Figure 1A). The chemistry explored used a 
tetrazine as a prodrug of a pyridazine (a common scaffold found 
in many drugs such as apresoline®, sulfamethoxypyridazine® 
and cadralazine®) and, in our case, generated the known 
microRNA 21 (miR21) inhibitor 2,31 leading to downregulation 
of oncogenic miR21 and consequently “switch-on” of apoptosis. 
The other prodrug (the dienophile) was the vinyl ether masked-
camptothecin 3 that liberated the anticancer drug 4, upon 
reaction with the tetrazine 1 (Figure 1B). Notably, for the first 
time, the tetrazine scaffold can be considered as a protecting 
group for bioactive pyridazines.  
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Figure 1. A) INVDA reaction between a vinyl ether masked drug (inactive) and the 
tetrazine masked drug (inactive) leads to an active drug pair (pyridazine and an 
alcohol). B) Reaction between the tetrazine prodrug 1 (masked pyridazine-based 
miR21 inhibitor 2) and the vinyl-O-camptothecin 3 (caged camptothecin 4) 
showing the dual and traceless prodrug-prodrug generation of 2 and 4. The 
inhibition of microRNA 21 and topoisomerase would lead to cell apoptosis. 
Results and Discussion 
Synthesis of Tetrazine-Prodrug 
Short non-coding microRNA (miRNA) strands play a critical role 
in several biological processes with dysregulation of miRNA 
being associated with numerous diseases, in particular 
cancer.32,33 Oncogenic miR21 downregulates apoptosis with 
miRNA inhibition resulting in notable increase in apoptosis. 
Pyridazine 2, an miR21 inhibitor,31 was readily synthesized in 
two steps, starting from 2,5-dichloropyridazine 5, via 2-chloro-
5-thiomethoxidepyridazine 6 (generated by reaction with 
sodium thiomethoxide) followed by a Suzuki coupling with 3-
nitrophenylboronic acid (Scheme 1A). Pyridazines34 can also be 
formed via INVDA reaction from the corresponding tetrazines 
and activated alkenes (Figure 1). Importantly, in the case of 2, 
the corresponding tetrazine prodrug 1 bears electron 
withdrawing and donating moieties which are known to 
increase reactivity and elimination of the alkoxide in INVDA 
chemistries.35 The synthesis of tetrazine 1 was achieved using 3-
nitrophenyl imidoester 7 as a precursor, which was readily 
accessible from 3-nitrobenzonitrile 8. In a facile route to 
tetrazines  7 treated with methyl thiocarbohydrazidium S7 gave 
2,4-dihydrotetrazine that was oxidized in situ with amyl nitrite 
to give the tetrazine prodrug 1 (Scheme 1B). 
 
The synthesis of tetrazine 1 was achieved using 3-nitrophenyl 
imidoester 7 as a precursor, which was readily accessible from 
3-nitrobenzonitrile 8. In a facile route to tetrazines  7 treated 
with methyl thiocarbohydrazidium S7 gave 2,4-
dihydrotetrazine that was oxidized in situ with amyl nitrite to 
give the tetrazine prodrug 1 (Scheme 1B).  
 
The miR21 inhibitor 2 and the tetrazine prodrug 1, were 
evaluated for their activity on breast, prostate and brain cancer 
cells (SK-BR3, PC3 and U87-MG, respectively), which all express 
miR21.36,37,38 No influence on cell viability was observed when 
the cells were treated with up to 10 µM of the tetrazine prodrug 
1; however, the same concentration of miR21 inhibitor 2 
resulted in reduced cell viability in all three cell lines (Figure 2), 
with the observed reduction in cell viability due to induced 
apoptosis, as shown by an Annexin V assay (Figure 2). 
 
The activation of the tetrazine prodrug 1 with a vinyl ether 
containing small molecule was then investigated. We 
postulated that 5'-O-vinyl deoxyuridine 9 would be a 
biocompatible, non-toxic dienophile, since the resulting alcohol 
is a naturally occurring nucleoside. Thus, deoxyuridine 11 was 
selectively alkylated with 1,2-dibromoethane to give 5'-O-
bromoethyldeoxyuridine 10. Substitution of the bromine with 
caesium phenylselenolate gave the phenylselenyl ether 12,39 
with oxidation with periodate giving 5'-O-vinyl deoxyuridine 9 
(Scheme 1C). 
 
Scheme 1. A) i) NaSCH3, NEt3 ii) 3-Nitrophenylboronic acid, Na2CO3, Pd(dppf), 
dioxane/H2O (4:1). B) i) HCl, EtOH/dioxane (1:1). ii) Methyl thiocarbohydrazidium 
S7, pyridine, DMF. iii) Amyl nitrite, CH2Cl2. C) i) 1,2-dibromoethane, NaH, DMF. ii) 
PhSeH, CsOH·H2O. iii) 1) NaIO4, NaHCO3, CH3OH/H2O (5:1); 2) DIPEA, CH3CN. 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
Figure 2. A) Reaction between tetrazine 1 and 5'-O-vinyl deoxyuridine 9 (see supporting information for HPLC analysis and reaction kinetics). B) U87-MG, SK-BK3 and 
PC3 cells incubated with tetrazine 1 (10 µM), 5’-O-vinyl deoxyuridine 9 (20 µM), miR21 inhibitor 2 (10 µM) and tetrazine 1 (10 µM) with 5’-O-vinyl deoxyuridine 9 (20 
µM). Cell viability measured after 72 h (MTT assay, n = 3). *** P < 0.001 and ** P < 0.01 by one-way ANOVA with Tukey post-test. No cytotoxicity was observed for 9 up 
to 20 µM C) Flow cytometry histograms of Annexin V assay (FITC labelled) for detection of apoptotic cells with tetrazine 1 (10 µM), miR21 inhibitor 2 (10 µM), 5'-O-vinyl 
deoxyuridine 9 (20 µM) and tetrazine 1 (10 µM) with 5'-O-vinyl deoxyuridine 9 (20 µM) after 14 h of incubation with SK-BR3.  
Cellular incubation of the 5'-O-vinyl nucleoside 9 (20 µM) 
confirmed the biocompatibility of the vinyl ether with no 
apoptosis of SK-BR3 cells observed.  The addition of tetrazine 
prodrug 1 (10 µM) with 9 (20 µM), however, gave equivalent 
levels of cell death as induced by the addition of 10 µM of pure 
inhibitor 2 (see Figure 2) with 30% of cells being positive in the 
Annexin assay (Figure 2 and S6), thus demonstrating in situ 
prodrug activation. 
Prodrug – Prodrug Activation 
Camptothecin 4 is a topoisomerase I inhibitor that induces S-
phase specific cell death. Since its discovery in the 1960’s, 
several camptothecin derivatives and prodrugs have been 
reported with the aim of overcoming the drawbacks associated 
with camptothecin such as solubility and the stability of the 
lactone ring, which has been shown to play a crucial role in 
inhibiting topoisomerase I.40,41 In particular, it has been shown 
that alkylation or acetylation of the hydroxy group at the C20 
position enhances the stability of the lactone ring;42 however, 
masking the hydroxy group of campthotecin causes a loss of its 
therapeutic efficiency with only a few examples known where 
the protecting group can be cleaved (usually by enzymatic 
triggering) without loss of activity.43,44 
 
Vinyl-O-camptothecin 3 was synthesized in a single step 
procedure by slightly modifying a reported iridium catalysed 
trans-vinylation reaction45 using 1,4-dioxane to overcome the 
poor solubility of camptothecin 4  and an excess of vinylacetate 
(Figure 3A). As postulated, masking the hydroxy group of 
camptothecin with a vinyl ether, caused a significant reduction 
in cytotoxicity, increasing the IC50 from 0.15 µM to 4.6 µM for 
PC3 cells and from 0.18 µM to 4.9 µM for SK-BR3 cells (Figure 3, 
and Figure S7).  
 
Treatment of vinyl-O-camptothecin 3 with the tetrazine 
prodrug 1 showed (monitored by HPLC) the generation of the 
active parent drug camptothecin 4 alongside the miR21 
inhibitor 2. HPLC analysis also indicated the formation of small 
quantities of the oxidized tetrazine and a small peak assigned to 
the oxidized pyridazine (Figure S5). Thus, this demasking 
generates two active drugs and resulted in controlled switch-on 
of cytotoxicity (Figure 4 and Figure S8). Importantly, co-
treatment of PC3 cells with 2 and 4 showed an additive effect 
beyond the decaging/activation of 1 alone with increased levels 
of dead cells compared to treatment with 2 or 4 (Figure S9). In 
addition, by masking the hydroxyl moiety, not only the IC50 
value is increasing but also its stability. We assume that the 
enhanced stability of prodrug 3 leads eventually to a higher 
concentration of the active drug 4. 
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Figure 3. A) i) Camptothecin 4, vinyl acetate, Na2CO3, [Ir(cod)Cl]2, 1,4-dioxane, 100 °C, 4 h. The reaction between tetrazine 1 and vinyl-O-camptothecin 3 gave > 85 % 
conversion (CH3OH/CH3CN/H2O) within 5 days as determined by HPLC. B) Cell viability of PC3 cells after incubation with vinyl-O-camptothecin 3 (IC50 = 4.64 ± 1.13 µM) 
and camptothecin 4 (IC50 = 0.15 ± 0.06 µM) for 72 h at 37 °C; insert is non-linear fit used to determine IC50 values (MTT assay, n = 3).  
Hydrolytic stability is a critical parameter for any tetrazine 
targeted for biological applications and the half-life of prodrug 
1 was determined to be 2.2 ± 0.04 days in DMSO/PBS, some 10-
fold higher than the widely used 3,6-di-2-pyridinyltetrazine S5 
(t1/2 = 0.31 ± 0.03 days in DMSO/PBS) (Figures S10–S13). 
Tetrazine 1 also exhibited reasonable stability in the presence 
of glutathione (5 mM GSH in DMSO/H2O) with 77 % of 1 
remaining after 3 days vs 88 % remaining without GSH (Figure 
S14).  
Conclusions 
In summary, we report for the first time a symbiotic prodrug– 
prodrug activation strategy that, in addition, fully complies with 
the principle of bioorthogonality. To illustrate the power of this  
 
Figure 4. Cell viability after treatment with tetrazine 1 (10 µM) = 95 ± 14 %, vinyl-
O-camptothecin 3 (0.5 µM) = 101 ± 10 %, co-treatment of tetrazine 1 (10 µM) and 
vinyl-O-camptothecin 3 (0.5 µM) = 47 ± 8 %, camptothecin 4 (0.5 µM) = 38 ± 5 %, 
(PC3, MTT-assay, n = 3) *** P < 0.001 by one-way ANOVA with Tukey post-test. 
 
new strategy, we showed that a tetrazine prodrug scaffold was 
converted into a pyridazine based miR21 inhibitor upon 
reaction and decaging of a vinyl ether masked camptothecin. 
This demasking takes advantage of the water acceleration 
effect (for water dependency of kinetics see Figure S1), which 
has been widely exploited and acknowledged in tetrazine 
chemistry18 and results in the activation of two drugs without 
the generation of by-products, such as the phosphine oxide 
seen in the Staudinger ligation. Since drug resistance is a major 
concern in anti-cancer therapy, which has been linked to an 
overexpression of miRNA,46 activation of a conventional anti-
cancer drug such as camptothecin in concert with a miR21 
inhibitor, offers a new bioorthogonal prodrug-prodrug 
activation strategy and is an exceptionally atom efficient 
method of prodrug activation. The dual/traceless prodrug–
prodrug activation strategy opens up new possibilities and 
directions in the field of drug delivery.  
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